查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2146919

聚左旋乳酸Sirolimus洗脫冠狀動脈支架系統市場：全球市場預測，2026-2032年

Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，聚左旋乳酸Sirolimus洗脫冠狀動脈支架系統市場將成長至 48 億美元，複合年成長率為 7.80%。

主要市場統計數據
基準年 2025 28.4億美元
預計年份：2026年 30.6億美元
預測年份 2032 48億美元
複合年成長率 (%) 7.80%

聚左旋乳酸Sirolimus緩釋冠狀動脈支架系統是一種可生物吸收的血管裝置，旨在支撐狹窄的冠狀動脈，同時釋放Sirolimus以抑制過度增生。其關鍵特性在於其聚合物支架可隨時間分解，與傳統的永久性金屬支架相比，血管癒合後殘留的材料可能較少。臨床評估主要關注手術成功率、徑向支撐強度、病變部位的貼合度、血管再阻塞、血栓症率、癒合情況和長期安全性。該產品的應用取決於證據品質、監管要求、醫生培訓、保險報銷以及現有替代裝置的可用性。

冠狀動脈支架設計與治療的變革性變化

該領域正從永久性植入轉向旨在將臨時機械支撐與可控藥物釋放並最終實現吸收相結合的裝置。這種轉變更重視聚合物的製備、支架厚度、部署精度、滲透性、分解行為、病灶的選擇。在治療路徑層面，血管內影像、病灶準備、雙重抗血小板治療和術後監測的改善正在影響新型支架的評估和應用。證據標準仍然嚴格，因為必須同時證明其初始機械性能和長期生物學結果。

人工智慧對醫療設備研發和應用的累積影響

人工智慧可以透過輔助影像解讀、病灶測量、器械尺寸選擇、手術方案規劃以及識別高風險不利事件患者來支持這一市場。在研發領域，機器學習技術可用於聚合物劣化分析、支架結構最佳化以及跨臨床和影像資料集的模式識別。然而，可靠的部署需要具有代表性的訓練資料、前瞻性檢驗、透明的效能評估、網路安全措施以及明確的臨床課責。人工智慧應作為輔助手段，而非取代臨床醫師的判斷和實證治療方案。

北美、拉丁美洲、歐洲、中東和非洲以及亞太地區的區域洞察。

北美地區的特點是臨床和監管審查嚴格、介入治療基礎設施先進，以及血管內影像和專科心臟中心資源豐富。歐洲擁有完善的導管介入網路，並結合各國不同的保險報銷和證據要求，歐盟內部的監管協調進一步增強了其優勢。亞太地區擁有高度發展的介入治療市場和快速發展的心血管醫療保健體系，因此訓練、成本效益和區域性證據尤其重要。拉丁美洲的介入治療應用環境因公共和私人保險覆蓋範圍、引進手術以及專科醫生的可及性而異。中東地區多個國家擁有集中化的三級醫療保健體系，而非洲在導管介入實驗室的可近性、醫療設備採購和後續追蹤的連續性方面則存在更大的差距。

對東協、金磚國家、歐盟、七國集團、海灣合作理事會和北約進行集團分析。

東協市場在報銷體系、監管成熟度和介入性心臟病學（心臟導管介入術）體系方面差異顯著，因此適合分階段實施，並輔以臨床醫生培訓和區域性證據。金磚國家對心血管醫療保健的需求龐大，但國內生產能力、採購系統和准入限制各不相同。歐盟強調通用的監管要求，同時保留各國在報銷體系和醫院採購上的差異。七國集團成員國通常擁有成熟的證據生成、影像學和上市後監測體系。海灣合作理事會國家受益於集中式的專業醫療保健基礎設施和跨境醫療保健網路，而北約成員國整體上醫療保健體系各異，其重要性更體現在韌性、採購連續性和對醫療技術的應對力上，而非統一的商業性管道。

主要冠狀動脈介入治療市場的特定國家趨勢

澳洲和加拿大在其公共醫療體系中高度重視臨床證據、專科實踐和價值評估。美國擁有強大的冠狀動脈介入治療能力和嚴格的醫療設備監管體系。在歐洲，法國、德國、義大利、西班牙和英國擁有強大的臨床能力，但在報銷、醫院採購和醫療技術評估方面存在差異。中國、印度、日本和韓國對心血管治療的需求龐大，但它們的監管、生產和臨床實踐環境各不相同。巴西和墨西哥在公立和私立醫療服務取得方面以及不同地區之間存在差異，而俄羅斯則擁有其獨特的監管和採購環境。在這些國家，該產品的推廣應用取決於其安全性、病變部位的選擇是否恰當、醫師的信心、價格是否合理、後續追蹤是否可靠。

生物可吸收冠狀動脈支架領域行業領導者可採取的優先事項

領導者應優先考慮來自隨機對照試驗和長期追蹤研究的可靠證據，明確定義患者族群、病變類型、手術方案和具有臨床意義的終點。產品開發應著重於植入可靠性、藥物控釋、可預測的吸收、可見性以及與現代影像和抗血小板療法的兼容性。市場准入計畫應符合各國的具體法規、報銷政策和醫院採購要求。系統性的醫生教育、手術指導、影像引導和透明的不利事件報告有助於安全部署。應充分利用與臨床中心的合作關係來累積在地化證據，同時保護資料管治和病患隱私。

調查方法執行摘要

本執行摘要分析了已界定的市場範圍（聚左旋乳酸Sirolimus洗脫冠狀動脈支架系統），重點在於技術特性、臨床啟動因素、監管法規、醫療基礎設施、區域因素和相關人員。本文的見解是基於冠狀動脈介入治療、醫療設備評估和醫療系統實施的既定原則，而非市場預測或商業性排名。區域、群體和國家層面的具體考量均採用比較和定性方法，反映了法律規範、臨床能力、報銷、採購和准入方面的差異。隨著同儕審查證據、監管決策、臨床指引和上市後研究結果的更新，本文的解讀也應隨之更新。

結論：基於實證醫學證據引入可吸收Sirolimus洗脫支架

聚左旋乳酸Sirolimus洗脫冠狀動脈支架系統將抗增殖療法與一種旨在血管不再需要支撐後自動吸收的支架相結合。其長期應用取決於手術操作的一致性、持續的臨床安全性、可靠的吸收以及足以證明其益處足以抵消與現有方案相比增加的複雜性的證據。製造商、臨床醫生、監管機構、保險公司和醫療保健系統在嚴格評估、適當的患者選擇、培訓和監測方面的合作有望取得最大進展。雖然人工智慧可能有助於改進計劃和檢驗生成，但經驗證的臨床結果仍必須是推廣應用的基礎。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：聚左旋乳酸Sirolimus洗脫冠狀動脈支架系統市場：依適應症分類

  • 急性冠狀動脈症候群
    • 非ST段抬高型心肌梗塞
    • ST段上升型心肌梗塞
    • 不穩定型心絞痛
  • 慢性冠狀動脈綜合症
    • 無症狀性
    • 穩定性心絞痛

第8章：聚左旋乳酸Sirolimus洗脫冠狀動脈支架系統市場：依病變類型分類

  • 新病變
  • 支架內再血管再阻塞

第9章：聚左旋乳酸Sirolimus洗脫冠狀動脈支架系統市場：依直徑分類

  • 2.5–3.0 毫米
    • 2.5毫米
    • 2.75毫米
    • 3.0毫米
  • 大於 3.0 毫米
    • 3.5毫米
    • 4.0毫米
  • 小於2.5毫米

第10章：聚左旋乳酸Sirolimus洗脫冠狀動脈支架系統市場：依長度分類

  • 18-28毫米
    • 18毫米
    • 24毫米
    • 28毫米
  • 超過28毫米
    • 32毫米
    • 38毫米
  • 小於18毫米
    • 12毫米
    • 16毫米

第11章：聚左旋乳酸Sirolimus洗脫冠狀動脈支架系統市場：依最終用戶分類

  • 門診手術中心
  • 醫院

第12章：聚左旋乳酸Sirolimus洗脫冠狀動脈支架系統市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 專業心臟病中心

第13章：聚左旋乳酸Sirolimus洗脫冠狀動脈支架系統市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章：聚左旋乳酸Sirolimus洗脫冠狀動脈支架系統市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：聚左旋乳酸Sirolimus洗脫冠狀動脈支架系統市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Biotronik SE & Co. KG
  • Elixir Medical Corp.
  • Lepu Medical Technology（Beijing）Co., Ltd.
  • Meril Life Sciences Private Limited
  • MicroPort Scientific Corporation
  • Reva Medical, Inc.

第18章 主要專家

Product Code: MRR-3D150775E49F

The Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market is projected to grow by USD 4.80 billion at a CAGR of 7.80% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.84 billion
Estimated Year [2026] USD 3.06 billion
Forecast Year [2032] USD 4.80 billion
CAGR (%) 7.80%

Poly-L-lactic acid sirolimus-eluting coronary stent systems are bioresorbable vascular devices designed to support a narrowed coronary artery while releasing sirolimus to reduce excessive tissue growth. Their distinguishing feature is a polymer scaffold intended to degrade over time, potentially leaving less permanent material after vascular healing than conventional permanent metallic platforms. Clinical evaluation focuses on procedural success, radial strength, lesion suitability, restenosis, thrombosis, healing, and long-term safety. Adoption is shaped by evidence quality, regulatory requirements, physician training, reimbursement, and the availability of established alternative devices.

Transformative Shifts in Coronary Stent Design and Care

The field is shifting from permanent implants toward devices intended to combine temporary mechanical support with controlled drug delivery and eventual resorption. This transition places greater emphasis on polymer processing, scaffold thickness, deployment accuracy, radiopacity, degradation behavior, and lesion selection. At the care-pathway level, improvements in intravascular imaging, lesion preparation, dual-antiplatelet management, and post-procedure surveillance are influencing how emerging scaffolds are evaluated and used. Evidence standards remain demanding because early mechanical performance and late biological outcomes must both be demonstrated.

Artificial Intelligence's Cumulative Impact on Device Development and Use

Artificial intelligence can support this market by assisting image interpretation, lesion measurement, device sizing, procedural planning, and identification of patients at elevated risk of adverse outcomes. In research and development, machine-learning methods may help analyze polymer degradation, optimize scaffold architecture, and detect patterns across clinical and imaging datasets. However, reliable deployment requires representative training data, prospective validation, transparent performance assessment, cybersecurity controls, and clear clinical accountability. AI should augment-not replace-operator judgment and evidence-based treatment protocols.

Regional Insights Across North America, Latin America, Europe, the Middle East, Africa, and Asia-Pacific

North America is characterized by stringent clinical and regulatory scrutiny, advanced interventional infrastructure, and broad access to intravascular imaging and specialized cardiac centers. Europe combines sophisticated catheterization networks with country-specific reimbursement and evidence requirements, while the European Union adds harmonized regulatory considerations. Asia-Pacific includes highly developed procedural markets alongside rapidly expanding cardiovascular-care capacity, making training, affordability, and local evidence especially important. Latin America's adoption environment varies with public-private coverage, import processes, and specialist availability. The Middle East is supported by concentrated tertiary-care capabilities in several countries, while Africa faces wider disparities in cath-lab access, device procurement, and follow-up continuity.

Group Insights Across ASEAN, BRICS, the European Union, G7, GCC, and NATO

ASEAN markets differ substantially in reimbursement, regulatory maturity, and interventional cardiology capacity, favoring staged adoption supported by clinician training and regional evidence. BRICS economies combine substantial cardiovascular-care needs with varied domestic manufacturing capabilities, procurement systems, and access constraints. The European Union emphasizes common regulatory expectations while retaining national differences in reimbursement and hospital purchasing. G7 members generally have mature evidence-generation, imaging, and post-market surveillance systems. GCC countries benefit from concentrated specialist infrastructure and cross-border care networks, whereas NATO members collectively include diverse health systems whose relevance lies in resilience, procurement continuity, and medical-technology readiness rather than a uniform commercial pathway.

Country Insights Across Major Coronary Intervention Markets

Australia and Canada place strong emphasis on clinical evidence, specialist practice, and public health-system value assessment. The United States has extensive interventional cardiology capacity and rigorous device oversight. In Europe, France, Germany, Italy, Spain, and the United Kingdom differ in reimbursement, hospital procurement, and health-technology assessment despite advanced clinical capabilities. China, India, Japan, and South Korea combine significant cardiovascular-care demand with distinct regulatory, manufacturing, and clinical-practice environments. Brazil and Mexico reflect varied public-private access and regional disparities, while Russia presents a distinct regulatory and procurement context. Across these countries, adoption depends on demonstrated safety, appropriate lesion selection, operator confidence, affordability, and dependable follow-up.

Actionable Priorities for Industry Leaders in Bioresorbable Coronary Stents

Leaders should prioritize robust randomized and long-term follow-up evidence, clearly defining patient populations, lesion types, procedural protocols, and clinically meaningful endpoints. Product development should focus on deployment reliability, controlled drug release, predictable resorption, visibility, and compatibility with contemporary imaging and antiplatelet practice. Market access plans should align regulatory, reimbursement, and hospital-procurement requirements country by country. Structured physician education, proctoring, imaging guidance, and transparent adverse-event reporting can support safe implementation. Partnerships with clinical centers should be used to build locally relevant evidence while preserving data governance and patient privacy.

Research Methodology for the Executive Summary

This executive summary uses the defined market scope-poly-L-lactic acid sirolimus-eluting coronary stent systems-and organizes analysis around technology characteristics, clinical adoption factors, regulation, care infrastructure, geography, and stakeholder needs. Insights are derived from established principles of coronary intervention, medical-device evaluation, and health-system implementation rather than market estimates or commercial rankings. Regional, group, and country discussions are comparative and qualitative, reflecting differences in regulatory structures, clinical capacity, reimbursement, procurement, and access. Interpretation should be updated as peer-reviewed evidence, regulatory decisions, clinical guidelines, and post-market findings evolve.

Conclusion: Evidence-led Adoption of Resorbable Sirolimus-eluting Stents

Poly-L-lactic acid sirolimus-eluting coronary stent systems represent an effort to pair antiproliferative therapy with a scaffold intended to disappear after vascular support is no longer required. Their long-term role will depend on consistent procedural performance, durable clinical safety, reliable resorption, and evidence that benefits justify added complexity relative to established options. Progress will be strongest where manufacturers, clinicians, regulators, payers, and health systems coordinate on rigorous evaluation, appropriate patient selection, training, and surveillance. Artificial intelligence may improve planning and evidence generation, but validated clinical outcomes must remain the foundation of adoption.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market, by Indication

  • 7.1. Introduction
  • 7.2. Acute Coronary Syndrome
    • 7.2.1. Non-ST-Elevation MI
    • 7.2.2. ST-Elevation MI
    • 7.2.3. Unstable Angina
  • 7.3. Chronic Coronary Syndrome
    • 7.3.1. Asymptomatic
    • 7.3.2. Stable Angina

8. Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market, by Lesion Type

  • 8.1. Introduction
  • 8.2. De Novo Lesions
  • 8.3. In-Stent Restenosis

9. Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market, by Diameter

  • 9.1. Introduction
  • 9.2. 2.5 to 3.0 Millimeter
    • 9.2.1. 2.5 Millimeter
    • 9.2.2. 2.75 Millimeter
    • 9.2.3. 3.0 Millimeter
  • 9.3. Greater Than 3.0 Millimeter
    • 9.3.1. 3.5 Millimeter
    • 9.3.2. 4.0 Millimeter
  • 9.4. Less Than 2.5 Millimeter

10. Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market, by Length

  • 10.1. Introduction
  • 10.2. Eighteen to Twenty-Eight Millimeter
    • 10.2.1. 18 Millimeter
    • 10.2.2. 24 Millimeter
    • 10.2.3. 28 Millimeter
  • 10.3. Greater Than Twenty-Eight Millimeter
    • 10.3.1. 32 Millimeter
    • 10.3.2. 38 Millimeter
  • 10.4. Less Than Eighteen Millimeter
    • 10.4.1. 12 Millimeter
    • 10.4.2. 16 Millimeter

11. Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market, by End User

  • 11.1. Introduction
  • 11.2. Ambulatory Surgical Centers
  • 11.3. Hospitals

12. Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market, by Distribution Channel

  • 12.1. Introduction
  • 12.2. Hospital Pharmacies
  • 12.3. Online Pharmacies
  • 12.4. Specialized Cardiac Centers

13. Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market, by Region

  • 13.1. Introduction
  • 13.2. Asia-Pacific
  • 13.3. North America
  • 13.4. Latin America
  • 13.5. Europe
  • 13.6. Middle East
  • 13.7. Africa

14. Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market, by Group

  • 14.1. Introduction
  • 14.2. ASEAN
  • 14.3. GCC
  • 14.4. European Union
  • 14.5. BRICS
  • 14.6. G7
  • 14.7. NATO

15. Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market, by Country

  • 15.1. Introduction
  • 15.2. United States
  • 15.3. Canada
  • 15.4. Mexico
  • 15.5. Brazil
  • 15.6. United Kingdom
  • 15.7. Germany
  • 15.8. France
  • 15.9. Russia
  • 15.10. Italy
  • 15.11. Spain
  • 15.12. China
  • 15.13. India
  • 15.14. Japan
  • 15.15. Australia
  • 15.16. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2025
  • 16.2. Market Concentration Analysis, 2025
    • 16.2.1. Concentration Ratio (CR)
    • 16.2.2. Herfindahl Hirschman Index (HHI)
  • 16.3. Recent Developments & Impact Analysis, 2025
  • 16.4. Product Portfolio Analysis, 2025
  • 16.5. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Biotronik SE & Co. KG
  • 17.2. Elixir Medical Corp.
  • 17.3. Lepu Medical Technology (Beijing) Co., Ltd.
  • 17.4. Meril Life Sciences Private Limited
  • 17.5. MicroPort Scientific Corporation
  • 17.6. Reva Medical, Inc.

18. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market, Years Considered for the Study
  • FIGURE 2. Global Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market, Research Design
  • FIGURE 3. Global Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market, Research Framework
  • FIGURE 4. Global Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market, Data Triangulation
  • FIGURE 5. Global Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Indication, 2025 vs 2032 (%)
  • FIGURE 7. Global Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Lesion Type, 2025 vs 2032 (%)
  • FIGURE 9. Global Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Lesion Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Diameter, 2025 vs 2032 (%)
  • FIGURE 11. Global Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Diameter, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Length, 2025 vs 2032 (%)
  • FIGURE 13. Global Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Length, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by End User, 2025 vs 2032 (%)
  • FIGURE 15. Global Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Distribution Channel, 2025 vs 2032 (%)
  • FIGURE 17. Global Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 18. Global Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 19. Global Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 20. Global Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 21. Global Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 22. Global Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 23. Global Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Segmentation & Coverage
  • TABLE 2. Global Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 4. Global Acute Coronary Syndrome Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Acute Coronary Syndrome Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Acute Coronary Syndrome Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Non-ST-Elevation MI Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Non-ST-Elevation MI Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Non-ST-Elevation MI Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global ST-Elevation MI Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global ST-Elevation MI Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global ST-Elevation MI Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global Unstable Angina Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 14. Global Unstable Angina Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 15. Global Unstable Angina Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 16. Global Chronic Coronary Syndrome Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 17. Global Chronic Coronary Syndrome Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 18. Global Chronic Coronary Syndrome Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 19. Global Asymptomatic Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 20. Global Asymptomatic Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 21. Global Asymptomatic Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 22. Global Stable Angina Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 23. Global Stable Angina Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 24. Global Stable Angina Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 25. Global Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Lesion Type, 2017-2032 (USD Million)
  • TABLE 26. Global De Novo Lesions Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 27. Global De Novo Lesions Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 28. Global De Novo Lesions Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 29. Global In-Stent Restenosis Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 30. Global In-Stent Restenosis Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 31. Global In-Stent Restenosis Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 32. Global Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Diameter, 2017-2032 (USD Million)
  • TABLE 33. Global 2.5 to 3.0 Millimeter Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 34. Global 2.5 to 3.0 Millimeter Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 35. Global 2.5 to 3.0 Millimeter Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 36. Global 2.5 Millimeter Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 37. Global 2.5 Millimeter Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 38. Global 2.5 Millimeter Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 39. Global 2.75 Millimeter Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 40. Global 2.75 Millimeter Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 41. Global 2.75 Millimeter Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 42. Global 3.0 Millimeter Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 43. Global 3.0 Millimeter Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 44. Global 3.0 Millimeter Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 45. Global Greater Than 3.0 Millimeter Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 46. Global Greater Than 3.0 Millimeter Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 47. Global Greater Than 3.0 Millimeter Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 48. Global 3.5 Millimeter Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 49. Global 3.5 Millimeter Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 50. Global 3.5 Millimeter Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 51. Global 4.0 Millimeter Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 52. Global 4.0 Millimeter Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 53. Global 4.0 Millimeter Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 54. Global Less Than 2.5 Millimeter Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 55. Global Less Than 2.5 Millimeter Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 56. Global Less Than 2.5 Millimeter Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 57. Global Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Length, 2017-2032 (USD Million)
  • TABLE 58. Global Eighteen to Twenty-Eight Millimeter Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 59. Global Eighteen to Twenty-Eight Millimeter Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 60. Global Eighteen to Twenty-Eight Millimeter Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 61. Global 18 Millimeter Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 62. Global 18 Millimeter Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 63. Global 18 Millimeter Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 64. Global 24 Millimeter Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 65. Global 24 Millimeter Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 66. Global 24 Millimeter Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 67. Global 28 Millimeter Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 68. Global 28 Millimeter Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 69. Global 28 Millimeter Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 70. Global Greater Than Twenty-Eight Millimeter Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 71. Global Greater Than Twenty-Eight Millimeter Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 72. Global Greater Than Twenty-Eight Millimeter Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 73. Global 32 Millimeter Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 74. Global 32 Millimeter Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 75. Global 32 Millimeter Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 76. Global 38 Millimeter Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 77. Global 38 Millimeter Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 78. Global 38 Millimeter Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 79. Global Less Than Eighteen Millimeter Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 80. Global Less Than Eighteen Millimeter Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 81. Global Less Than Eighteen Millimeter Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 82. Global 12 Millimeter Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 83. Global 12 Millimeter Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 84. Global 12 Millimeter Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 85. Global 16 Millimeter Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 86. Global 16 Millimeter Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 87. Global 16 Millimeter Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 88. Global Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 89. Global Ambulatory Surgical Centers Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 90. Global Ambulatory Surgical Centers Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 91. Global Ambulatory Surgical Centers Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 92. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 93. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 94. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 95. Global Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 96. Global Hospital Pharmacies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 97. Global Hospital Pharmacies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 98. Global Hospital Pharmacies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 99. Global Online Pharmacies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 100. Global Online Pharmacies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 101. Global Online Pharmacies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 102. Global Specialized Cardiac Centers Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 103. Global Specialized Cardiac Centers Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 104. Global Specialized Cardiac Centers Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 105. Global Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 106. Asia-Pacific Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 107. Asia-Pacific Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 108. Asia-Pacific Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Acute Coronary Syndrome, 2017-2032 (USD Million)
  • TABLE 109. Asia-Pacific Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Chronic Coronary Syndrome, 2017-2032 (USD Million)
  • TABLE 110. Asia-Pacific Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Lesion Type, 2017-2032 (USD Million)
  • TABLE 111. Asia-Pacific Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Diameter, 2017-2032 (USD Million)
  • TABLE 112. Asia-Pacific Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by 2.5 to 3.0 Millimeter, 2017-2032 (USD Million)
  • TABLE 113. Asia-Pacific Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Greater Than 3.0 Millimeter, 2017-2032 (USD Million)
  • TABLE 114. Asia-Pacific Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Length, 2017-2032 (USD Million)
  • TABLE 115. Asia-Pacific Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Eighteen to Twenty-Eight Millimeter, 2017-2032 (USD Million)
  • TABLE 116. Asia-Pacific Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Greater Than Twenty-Eight Millimeter, 2017-2032 (USD Million)
  • TABLE 117. Asia-Pacific Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Less Than Eighteen Millimeter, 2017-2032 (USD Million)
  • TABLE 118. Asia-Pacific Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 119. Asia-Pacific Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 120. North America Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 121. North America Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 122. North America Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Acute Coronary Syndrome, 2017-2032 (USD Million)
  • TABLE 123. North America Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Chronic Coronary Syndrome, 2017-2032 (USD Million)
  • TABLE 124. North America Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Lesion Type, 2017-2032 (USD Million)
  • TABLE 125. North America Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Diameter, 2017-2032 (USD Million)
  • TABLE 126. North America Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by 2.5 to 3.0 Millimeter, 2017-2032 (USD Million)
  • TABLE 127. North America Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Greater Than 3.0 Millimeter, 2017-2032 (USD Million)
  • TABLE 128. North America Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Length, 2017-2032 (USD Million)
  • TABLE 129. North America Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Eighteen to Twenty-Eight Millimeter, 2017-2032 (USD Million)
  • TABLE 130. North America Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Greater Than Twenty-Eight Millimeter, 2017-2032 (USD Million)
  • TABLE 131. North America Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Less Than Eighteen Millimeter, 2017-2032 (USD Million)
  • TABLE 132. North America Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 133. North America Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 134. Latin America Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 135. Latin America Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 136. Latin America Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Acute Coronary Syndrome, 2017-2032 (USD Million)
  • TABLE 137. Latin America Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Chronic Coronary Syndrome, 2017-2032 (USD Million)
  • TABLE 138. Latin America Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Lesion Type, 2017-2032 (USD Million)
  • TABLE 139. Latin America Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Diameter, 2017-2032 (USD Million)
  • TABLE 140. Latin America Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by 2.5 to 3.0 Millimeter, 2017-2032 (USD Million)
  • TABLE 141. Latin America Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Greater Than 3.0 Millimeter, 2017-2032 (USD Million)
  • TABLE 142. Latin America Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Length, 2017-2032 (USD Million)
  • TABLE 143. Latin America Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Eighteen to Twenty-Eight Millimeter, 2017-2032 (USD Million)
  • TABLE 144. Latin America Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Greater Than Twenty-Eight Millimeter, 2017-2032 (USD Million)
  • TABLE 145. Latin America Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Less Than Eighteen Millimeter, 2017-2032 (USD Million)
  • TABLE 146. Latin America Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 147. Latin America Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 148. Europe Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 149. Europe Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 150. Europe Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Acute Coronary Syndrome, 2017-2032 (USD Million)
  • TABLE 151. Europe Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Chronic Coronary Syndrome, 2017-2032 (USD Million)
  • TABLE 152. Europe Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Lesion Type, 2017-2032 (USD Million)
  • TABLE 153. Europe Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Diameter, 2017-2032 (USD Million)
  • TABLE 154. Europe Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by 2.5 to 3.0 Millimeter, 2017-2032 (USD Million)
  • TABLE 155. Europe Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Greater Than 3.0 Millimeter, 2017-2032 (USD Million)
  • TABLE 156. Europe Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Length, 2017-2032 (USD Million)
  • TABLE 157. Europe Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Eighteen to Twenty-Eight Millimeter, 2017-2032 (USD Million)
  • TABLE 158. Europe Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Greater Than Twenty-Eight Millimeter, 2017-2032 (USD Million)
  • TABLE 159. Europe Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Less Than Eighteen Millimeter, 2017-2032 (USD Million)
  • TABLE 160. Europe Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 161. Europe Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 162. Middle East Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 163. Middle East Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 164. Middle East Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Acute Coronary Syndrome, 2017-2032 (USD Million)
  • TABLE 165. Middle East Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Chronic Coronary Syndrome, 2017-2032 (USD Million)
  • TABLE 166. Middle East Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Lesion Type, 2017-2032 (USD Million)
  • TABLE 167. Middle East Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Diameter, 2017-2032 (USD Million)
  • TABLE 168. Middle East Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by 2.5 to 3.0 Millimeter, 2017-2032 (USD Million)
  • TABLE 169. Middle East Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Greater Than 3.0 Millimeter, 2017-2032 (USD Million)
  • TABLE 170. Middle East Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Length, 2017-2032 (USD Million)
  • TABLE 171. Middle East Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Eighteen to Twenty-Eight Millimeter, 2017-2032 (USD Million)
  • TABLE 172. Middle East Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Greater Than Twenty-Eight Millimeter, 2017-2032 (USD Million)
  • TABLE 173. Middle East Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Less Than Eighteen Millimeter, 2017-2032 (USD Million)
  • TABLE 174. Middle East Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 175. Middle East Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 176. Africa Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 177. Africa Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 178. Africa Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Acute Coronary Syndrome, 2017-2032 (USD Million)
  • TABLE 179. Africa Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Chronic Coronary Syndrome, 2017-2032 (USD Million)
  • TABLE 180. Africa Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Lesion Type, 2017-2032 (USD Million)
  • TABLE 181. Africa Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Diameter, 2017-2032 (USD Million)
  • TABLE 182. Africa Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by 2.5 to 3.0 Millimeter, 2017-2032 (USD Million)
  • TABLE 183. Africa Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Greater Than 3.0 Millimeter, 2017-2032 (USD Million)
  • TABLE 184. Africa Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Length, 2017-2032 (USD Million)
  • TABLE 185. Africa Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Eighteen to Twenty-Eight Millimeter, 2017-2032 (USD Million)
  • TABLE 186. Africa Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Greater Than Twenty-Eight Millimeter, 2017-2032 (USD Million)
  • TABLE 187. Africa Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Less Than Eighteen Millimeter, 2017-2032 (USD Million)
  • TABLE 188. Africa Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 189. Africa Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 190. Global Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 191. ASEAN Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 192. ASEAN Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 193. ASEAN Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Acute Coronary Syndrome, 2017-2032 (USD Million)
  • TABLE 194. ASEAN Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Chronic Coronary Syndrome, 2017-2032 (USD Million)
  • TABLE 195. ASEAN Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Lesion Type, 2017-2032 (USD Million)
  • TABLE 196. ASEAN Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Diameter, 2017-2032 (USD Million)
  • TABLE 197. ASEAN Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by 2.5 to 3.0 Millimeter, 2017-2032 (USD Million)
  • TABLE 198. ASEAN Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Greater Than 3.0 Millimeter, 2017-2032 (USD Million)
  • TABLE 199. ASEAN Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Length, 2017-2032 (USD Million)
  • TABLE 200. ASEAN Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Eighteen to Twenty-Eight Millimeter, 2017-2032 (USD Million)
  • TABLE 201. ASEAN Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Greater Than Twenty-Eight Millimeter, 2017-2032 (USD Million)
  • TABLE 202. ASEAN Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Less Than Eighteen Millimeter, 2017-2032 (USD Million)
  • TABLE 203. ASEAN Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 204. ASEAN Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 205. GCC Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 206. GCC Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 207. GCC Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Acute Coronary Syndrome, 2017-2032 (USD Million)
  • TABLE 208. GCC Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Chronic Coronary Syndrome, 2017-2032 (USD Million)
  • TABLE 209. GCC Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Lesion Type, 2017-2032 (USD Million)
  • TABLE 210. GCC Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Diameter, 2017-2032 (USD Million)
  • TABLE 211. GCC Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by 2.5 to 3.0 Millimeter, 2017-2032 (USD Million)
  • TABLE 212. GCC Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Greater Than 3.0 Millimeter, 2017-2032 (USD Million)
  • TABLE 213. GCC Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Length, 2017-2032 (USD Million)
  • TABLE 214. GCC Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Eighteen to Twenty-Eight Millimeter, 2017-2032 (USD Million)
  • TABLE 215. GCC Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Greater Than Twenty-Eight Millimeter, 2017-2032 (USD Million)
  • TABLE 216. GCC Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Less Than Eighteen Millimeter, 2017-2032 (USD Million)
  • TABLE 217. GCC Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 218. GCC Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 219. European Union Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 220. European Union Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 221. European Union Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Acute Coronary Syndrome, 2017-2032 (USD Million)
  • TABLE 222. European Union Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Chronic Coronary Syndrome, 2017-2032 (USD Million)
  • TABLE 223. European Union Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Lesion Type, 2017-2032 (USD Million)
  • TABLE 224. European Union Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Diameter, 2017-2032 (USD Million)
  • TABLE 225. European Union Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by 2.5 to 3.0 Millimeter, 2017-2032 (USD Million)
  • TABLE 226. European Union Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Greater Than 3.0 Millimeter, 2017-2032 (USD Million)
  • TABLE 227. European Union Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Length, 2017-2032 (USD Million)
  • TABLE 228. European Union Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Eighteen to Twenty-Eight Millimeter, 2017-2032 (USD Million)
  • TABLE 229. European Union Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Greater Than Twenty-Eight Millimeter, 2017-2032 (USD Million)
  • TABLE 230. European Union Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Less Than Eighteen Millimeter, 2017-2032 (USD Million)
  • TABLE 231. European Union Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 232. European Union Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 233. BRICS Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 234. BRICS Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 235. BRICS Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Acute Coronary Syndrome, 2017-2032 (USD Million)
  • TABLE 236. BRICS Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Chronic Coronary Syndrome, 2017-2032 (USD Million)
  • TABLE 237. BRICS Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Lesion Type, 2017-2032 (USD Million)
  • TABLE 238. BRICS Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Diameter, 2017-2032 (USD Million)
  • TABLE 239. BRICS Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by 2.5 to 3.0 Millimeter, 2017-2032 (USD Million)
  • TABLE 240. BRICS Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Greater Than 3.0 Millimeter, 2017-2032 (USD Million)
  • TABLE 241. BRICS Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Length, 2017-2032 (USD Million)
  • TABLE 242. BRICS Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Eighteen to Twenty-Eight Millimeter, 2017-2032 (USD Million)
  • TABLE 243. BRICS Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Greater Than Twenty-Eight Millimeter, 2017-2032 (USD Million)
  • TABLE 244. BRICS Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Less Than Eighteen Millimeter, 2017-2032 (USD Million)
  • TABLE 245. BRICS Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 246. BRICS Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 247. G7 Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 248. G7 Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 249. G7 Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Acute Coronary Syndrome, 2017-2032 (USD Million)
  • TABLE 250. G7 Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Chronic Coronary Syndrome, 2017-2032 (USD Million)
  • TABLE 251. G7 Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Lesion Type, 2017-2032 (USD Million)
  • TABLE 252. G7 Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Diameter, 2017-2032 (USD Million)
  • TABLE 253. G7 Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by 2.5 to 3.0 Millimeter, 2017-2032 (USD Million)
  • TABLE 254. G7 Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Greater Than 3.0 Millimeter, 2017-2032 (USD Million)
  • TABLE 255. G7 Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Length, 2017-2032 (USD Million)
  • TABLE 256. G7 Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Eighteen to Twenty-Eight Millimeter, 2017-2032 (USD Million)
  • TABLE 257. G7 Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Greater Than Twenty-Eight Millimeter, 2017-2032 (USD Million)
  • TABLE 258. G7 Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Less Than Eighteen Millimeter, 2017-2032 (USD Million)
  • TABLE 259. G7 Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 260. G7 Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 261. NATO Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 262. NATO Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 263. NATO Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Acute Coronary Syndrome, 2017-2032 (USD Million)
  • TABLE 264. NATO Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Chronic Coronary Syndrome, 2017-2032 (USD Million)
  • TABLE 265. NATO Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Lesion Type, 2017-2032 (USD Million)
  • TABLE 266. NATO Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Diameter, 2017-2032 (USD Million)
  • TABLE 267. NATO Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by 2.5 to 3.0 Millimeter, 2017-2032 (USD Million)
  • TABLE 268. NATO Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Greater Than 3.0 Millimeter, 2017-2032 (USD Million)
  • TABLE 269. NATO Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Length, 2017-2032 (USD Million)
  • TABLE 270. NATO Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Eighteen to Twenty-Eight Millimeter, 2017-2032 (USD Million)
  • TABLE 271. NATO Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Greater Than Twenty-Eight Millimeter, 2017-2032 (USD Million)
  • TABLE 272. NATO Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by Less Than Eighteen Millimeter, 2017-2032 (USD Million)
  • TABLE 273. NATO Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 274. NATO Poly-L-lactic Acid Sirolimus-eluting Coronary Stent System Market Size, b